Latest:
Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems
© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Authors
Dinakaran Balasubramanian
Dinakaran is an accomplished commercial professional with rich experience of over 12 years in the pharmaceutical industry. He has an extensive understanding of the US commercial landscape and its key economic drivers, specifically in generic injectables and biosimilars. He is currently serving as the Head of Commercial Strategy & Insights for Biologics in North America for Dr Reddys Laboratories. His role extends to providing valuable insights into pricing considerations, competitive intelligence, and market dynamics, crucial for driving product adoption and profitability objectives. During his long tenure, he has handled multiple roles across Sales, strategy, pricing, and product management.
Latest:
The Underlying Economics of Unbranded Biologics
Unbranded biologics primarily serve to uphold inflated list prices, typically prompted by loss of exclusivity, aiming to safeguard market share and counter biosimilar competition, although forthcoming legislative changes targeting high drug costs could lessen their significance moving forward.
Travis Brewer
Travis Brewer serves as the vice president of payer and public health strategy at Texas Oncology.
Latest:
Enhancing Biosimilar Adoption in Value-Based Oncology Care
Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.
Josh Canavan, PharmD
head of pharmacy at RazorMetrics
Latest:
Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.
James D. Chambers, PhD, MPharm, MSc
James D. Chambers, PhD, MPharm, MSc, is an associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies. Chambers leads the Tufts Medical Center Specialty Drug Evidence and Coverage Database and the Medicare National Coverage Decisions Database, making him a key expert in analyzing drug policy, reimbursement trends, and health care economics. Chambers is also partnering with Organon to share his insights as a health economist around the complex landscape of biosimilars.
Latest:
The Banking of Biosimilars: Insights From a Leading Health Economist
Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Advertisement
Advertisement